Skip to main content
TipRanks
Go Ultimate75% OFF

Corcept Therapeutics (CORT) AI Stock Analysis

1,349 Followers
CORT

Corcept Therapeutics

(NASDAQ:CORT)

Select Model
Rating:71Outperform
Price Target:$76.00â–²(8.46% Upside)
Action:upgraded
Date:11/04/26

CORT scores well on financial quality (strong cash generation and a very low-debt balance sheet) and is supported by a highly constructive earnings update with reiterated guidance and meaningful pipeline/commercial momentum. The score is held back by weak technicals (bearish trend despite oversold readings) and a rich valuation (high P/E with no dividend yield provided).

Positive Factors
Strong revenue growth and product adoptionRapid growth across the established endocrinology business and newly launched Lifyorli indicates expanding commercial reach and demand. Increasing physician and patient adoption can support durable revenue gains as Corcept broadens its presence across endocrine and oncology markets.
Negative Factors
Operating margin compressionLower operating profitability suggests that expenses or nonrecurring impacts are absorbing more of Corcept’s revenue growth. If this persists, earnings may scale less efficiently, limiting the benefit of strong sales momentum and reducing funds available for reinvestment.

Corcept Therapeutics Key Performance Indicators (KPIs)

Research & Development Expense BreakdownAllocation of R&D spending across programs and trial stages reveals how Corcept is prioritizing its pipeline—whether cash is focused on late‑stage clinical trials that could produce near‑term approvals and revenue, or on early discovery that points to longer‑term growth. Changes in the mix and absolute R&D spend also signal the company’s cash burn and financing needs, the surface area for regulatory and clinical risk, and how management balances short‑term commercial support with long‑term drug development.

$0.00$20.00M$40.00M$60.00MMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26Sep 26
Chart Insights

R&D spending is clearly being reallocated: after a multi‑quarter surge in hypercortisolism investment (driving Cushing’s/relacorilant activity), a sharp Q2‑2026 drop points to a transition from late‑stage development to regulatory/commercial execution—consistent with Lifyorli’s approval and management’s commercial focus—while oncology and pre‑clinical/ALS budgets are ramping, and unallocated/stock‑comp costs are rising as the company scales. That shift supports the raised 2026 guidance but raises execution risk if reduced metabolic R&D limits future indication expansion.

Data provided by:The Fly

Corcept Therapeutics (CORT) vs. SPDR S&P 500 ETF (SPY)

-75%-50%-25%0%25%50%75%CORT-9.34%SPY+13.46%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$7.67B
Dividend Yield
―
Average Volume (3M)
1.25M
Price to Earnings (P/E)
46.5
Beta (1Y)
0.35
Revenue Growth
30.02%
EPS Growth
48.80%
Country
US
Employees
730
Sector
General
Sector Strength
55
Industry
Medical - Pharmaceuticals

Corcept Therapeutics Business Overview & Revenue Model

Company Description

Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychia...

How the Company Makes Money

Corcept primarily makes money from net product revenue generated by sales of its marketed drug, Korlym (mifepristone), in the United States. Revenue is recognized from product shipments/sales to customers, net of estimated allowances such as product...

Corcept Therapeutics Earnings Call Summary

Earnings Call Date:Nov 03, 2026(Q3-2026)|% Change Since:-14.48%|Next Earnings Date:Mar 02, 2027
Earnings Call SentimentPositive

The call was strongly positive, with substantial revenue and net-income growth, record endocrinology performance, rapid Lifyorli adoption, positive clinical results and multiple advancing pipeline programs. The company also reiterated its 2026 revenue guidance and highlighted significant future opportunities in Cushing's syndrome, oncology, MASH and ALS. The main negatives were the prior complete response letter for relacorilant, the continuing underdiagnosis of hypercortisolism, the unmet need in platinum-resistant ovarian cancer and limited available information on a potential competing therapy.

Positive Updates

Strong Third-Quarter Financial Performance
Third-quarter 2026 revenue was $340.5 million, increasing 33% from the second quarter and 64% compared with the prior-year period. Net income was $126.8 million, compared with $43 million in Q2 and $19.7 million in the prior-year period.

Negative Updates

Prior Complete Response Letter for Relacorilant
The company originally submitted the relacorilant NDA approximately 20 months before the call and received a complete response letter at the end of the prior year. The FDA subsequently requested a specific global statistical test before the company resubmitted the NDA.

Company Guidance

Corcept reiterated its 2026 revenue guidance of $1.1 billion to $1.2 billion, with the midpoint of the range as its best thinking, and said it expects growth to continue; it expects its current Cushing's syndrome business to generate at least $2 billion in annual revenue by the end of this decade, with the availability of relacorilant driving faster growth to between $3 billion and $5 billion in 2030, while Lifyorli is expected to generate more than $1 billion. The company expects results from its BELLA, TRIDENT and SYNERGY studies by the end of next year, plans to begin a Phase III study in ALS next year, and will soon start a Phase II MASH trial evaluating 100 milligrams of miricorilant daily.

Corcept Therapeutics Financial Statement Overview

Summary

High-quality fundamentals: strong TTM revenue growth (~16%) with attractive net margin (~16.6%), very conservative leverage (debt-to-equity ~0.01), and robust/free-cash-flow strength (TTM FCF ~$195M; ~82% growth) with solid cash conversion (~0.98 FCF/NI). The main constraint is the recent step-down in operating margin and moderated return efficiency versus prior years.

Income Statement

78Positive

Balance Sheet

92Very Positive

Cash Flow

88Very Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue963.65M761.41M675.04M482.38M401.86M365.98M
Gross Profit949.55M748.43M664.16M475.89M396.47M360.70M
EBITDA134.40M68.35M162.83M126.92M119.64M127.95M
Net Income162.00M99.65M139.73M106.14M101.42M112.51M
Balance Sheet
Total Assets1.03B836.65M840.55M621.52M583.43M423.76M
Cash, Cash Equivalents and Short-Term Investments370.70M372.15M383.33M368.22M431.67M223.53M
Total Debt8.99M6.11M6.94M151.00K1.14M526.00K
Total Liabilities200.29M188.85M160.96M114.81M81.59M47.95M
Stockholders Equity833.74M647.80M679.59M506.70M501.84M375.81M
Cash Flow
Free Cash Flow194.62M141.78M195.90M126.90M119.91M167.42M
Operating Cash Flow198.11M142.00M198.07M127.04M120.32M167.89M
Investing Cash Flow-168.53M69.76M-177.60M90.91M-114.33M136.13M
Financing Cash Flow-56.38M-220.37M-28.35M-148.72M-17.28M-302.59M

Corcept Therapeutics Technical Analysis

Technical Analysis SentimentNegative
Last Price70.07

Price Trends

50DMA101.97Negative
100DMA103.29Negative
200DMA76.79Negative

Market Momentum

MACD-9.76Positive
RSI25.30Positive
STOCH13.82Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CORT, the sentiment is Negative. The current price of 70.07 is below the 20-day moving average (MA) of 81.63, below the 50-day MA of 101.97, and below the 200-day MA of 76.79, indicating a bearish trend. The MACD of -9.76 indicates Positive momentum. The RSI at 25.30 is Positive, neither overbought nor oversold. The STOCH value of 13.82 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CORT.

Corcept Therapeutics Risk Analysis

Corcept Therapeutics disclosed 29 risk factors in its most recent earnings report. Corcept Therapeutics reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.The use of artificial intelligence ("AI") by us and our vendors could adversely affect our business.Q3, 2026
2.Federal legislative and regulatory efforts to implement reference pricing or most-favored-nation pricing models could impact our future product revenues and materially harm our business.Q3, 2026
3.Federal legislative and regulatory efforts to implement reference pricing or most-favored-nation pricing models could impact our future product revenues and materially harm our business.Q2, 2026

Corcept Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

CORT against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
KNSAKNSA80Outperform$7.47B66.0817.27%―58.19%192.34%
CORTCORT71Outperform$7.67B46.5522.94%―30.02%48.80%
LQDALQDA60Neutral$5.11B-54.32-116.64%―798.44%27.88%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
SCYXSCYX53Neutral$28.37M-2.44-18.65%―543.96%72.49%
CTORCTOR44Neutral$50.92M-1.20-102.97%―――
NSRXNSRX28Underperform$30.57M-2.54-158.83%―――

* General Sector Average

Performance Comparison

0%100%200%CORTSCYXKNSALQDACTORNSRXDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
CORT and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
CORTCorcept Therapeutics70.07-4.98-6.64%
SCYXSCYNEXIS Inc2.85-2.67-48.37%
KNSAKiniksa Pharmaceuticals Ltd. Class A95.1153.62129.24%
LQDALiquidia Technologies56.7328.1798.63%
CTORCitius Oncology, Inc.0.55-0.58-51.59%
NSRXNasus Pharma Ltd.2.61-4.39-62.71%

Corcept Therapeutics Corporate Events

Financial DisclosuresProduct-Related Announcements

Corcept Therapeutics Reports Strong Third-Quarter Revenue and Earnings Growth

Positive
Nov 3, 2026

On November 3, 2026, Corcept reported third-quarter revenue of $340.5 million, up 64% from the same period in 2025. Net income rose to $126.8 million from $19.7 million, while diluted earnings per share increased to $1.01 from $0.16 and cash and inve...

Business Operations and StrategyExecutive/Board Changes

Corcept Therapeutics Announces New Endocrinology Division President

Positive
Sep 23, 2026

On September 22, 2026, Corcept Therapeutics said Sean Maduck, president of its Endocrinology division, notified the board he would resign effective October 1, 2026, after a 14-year tenure in which he helped expand treatment for patients with Cushing’...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 04, 2026